Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected to Post Quarterly Sales of $15.48 Million

Equities analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating) to announce sales of $15.48 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Mirum Pharmaceuticals’ earnings. The highest sales estimate is $19.49 million and the lowest is $13.60 million. Mirum Pharmaceuticals posted sales of $11.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 40.7%. The company is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Mirum Pharmaceuticals will report full-year sales of $69.77 million for the current financial year, with estimates ranging from $60.76 million to $83.23 million. For the next fiscal year, analysts expect that the business will post sales of $156.06 million, with estimates ranging from $142.40 million to $171.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) last announced its earnings results on Thursday, May 5th. The company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.39) by $0.22. Mirum Pharmaceuticals had a negative net margin of 218.74% and a negative return on equity of 163.01%. During the same period in the previous year, the business earned ($1.68) earnings per share.

Several research analysts recently issued reports on MIRM shares. Raymond James increased their price target on shares of Mirum Pharmaceuticals from $70.00 to $74.00 and gave the stock a “strong-buy” rating in a report on Friday, March 11th. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $64.00 to $69.00 and gave the stock a “buy” rating in a report on Monday, May 23rd. Zacks Investment Research cut shares of Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, SVB Leerink increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, May 24th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $47.67.

NASDAQ MIRM opened at $24.76 on Friday. The stock has a market capitalization of $788.23 million, a P/E ratio of -10.96 and a beta of 1.23. Mirum Pharmaceuticals has a 52-week low of $12.82 and a 52-week high of $28.65. The firm has a 50-day moving average price of $24.52 and a 200 day moving average price of $20.28.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Polar Capital Holdings Plc acquired a new position in Mirum Pharmaceuticals during the first quarter worth about $21,441,000. Prosight Management LP acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at approximately $1,628,000. Rock Springs Capital Management LP grew its position in shares of Mirum Pharmaceuticals by 8.3% in the first quarter. Rock Springs Capital Management LP now owns 1,666,208 shares of the company’s stock valued at $36,690,000 after purchasing an additional 127,394 shares during the last quarter. Delphia USA Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at approximately $241,000. Finally, State Street Corp grew its position in shares of Mirum Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 132,744 shares of the company’s stock valued at $2,923,000 after purchasing an additional 9,009 shares during the last quarter. Institutional investors own 87.68% of the company’s stock.

Mirum Pharmaceuticals Company Profile (Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

Featured Articles

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.